



IFW

Docket No. T2315-907327US02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Laszlo Prokai :
Serial No.: 10/801,695 : Art Unit:
Filed: March 17, 2004 :
For: Antagonists of RF-Amide Neuropeptides : Examiner:

INFORMATION DISCLOSURE STATEMENT

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with Applicants duty of disclosure, the following information is submitted for consideration by the U.S. Patent and Trademark Office in connection with the above-identified application.

Since this statement is filed after three (3) months of the filing date of this application, but prior to the mailing of the first office action, no fee is believed to be required.

The application relies, under 35 USC §120, on the earlier filing date of prior U.S. Application Serial No. 10/109,000, filed March 29, 2002. The references identified on the attached Form PTO-1449 were submitted to and/or cited by the applicant or the Patent Office in the prior application and, therefore copies are not required to be provided. (see 37 CFR §1.98(d)).

It is respectfully requested that the Examiner fully consider each of the documents, initial the enclosed Form PTO-1449 in the appropriate place to indicate that the document has been considered, and return a copy of the initialed form to the undersigned in accordance with MPEP Section 609.

Respectfully submitted,

MILES & STOCKBRIDGE




Dennis P. Clarke
Registration No. 22,549

Filed: June 18, 2004

Customer No. 000181

1751 Pinnacle Drive
Suite 500
McLean, Virginia 22102-3833
Telephone: (703) 903-9000
Facsimile: (703) 610-8686



PATENT & TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. T2315-907327US02	SERIAL NUMBER <i>10/801,695</i>
	APPLICANT	
	Laszlo Prokai	
	FILING DATE March 17, 2004	GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS

<u>EXAMINER INITIAL</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUB CLASS</u>	<u>FILING DATE</u>
	4,988,701	1/29/1991	Olney	514	318	8/25/89
	5,011,853	4/30/1991	Olney	514	454	1/26/90
	6,323,239	11/27/2001	Dewey et al.	514	561	8/9/00
	6,541,520	4/1/2003	Dewey et al.	514	561	12/11/98
	6,562,364	5/13/2003	DiSanto et al.	424	434	3/13/01
	6,566,400	5/20/2003	Akunne et al.	514	561	8/29/00
	6,593,367	7/15/2003	Dewey et al.	514	561	7/28/99

FOREIGN PATENT DOCUMENTS

<u>EXAMINER INITIAL</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUB CLASS</u>	<u>FILING DATE</u>
	2,002,006,274	1/2002	WO [by Sum, Fuk-Wah et al.]			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.

PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. T2315-907327US02	SERIAL NUMBER <i>10/801,695</i>
	APPLICANT	
	Laszlo Prokai	
	FILING DATE March 17, 2004	GROUP ART UNIT 1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Elshourbagy, et al., J. Biol. Chem. Chem. 2000, 275, 25965-25971
	Bonini, et al., J. Biol. Chem. 2000, 275, 39324-39331
	Yang et al., Proc. Natl. Acad. Sci., 1985, 82, 7757-61
	Yang et al., Prog. Clin. Biol. Res., 1985, 192, 313-22
	Panula et al., Med. Biology, 1987, 65, 127-35
	Kivipelto et al., Journal of Comparative Neurology
	Ferrarese et al., Regulatory Peptides, 1986, 13, 245-52
	Tang et al., Proc. Natl. Acad. Sci., 1984, 81, 5002-5
	Kavaliers et al., Peptides, 1989, 10, 741-5
	Kavaliers et al., Peptides, 1991, 12, 235-239
	Malin et al., Peptides, 1990, 11, 969-972
	Malin et al., Peptides, 1990, 11, 277-280
	Malin et al., Peptides, 1991, 12, 1011-4
	Malin et al., Drug Alcohol Depend. 1995, 40, 37-42
	Guzman et al., Neuropeptides 1989, 14, 253-261
	Majane et al., Peptides, 1987, 8, 657-662
	Majane et al., Peptides, 1988, 9, 1137-1144
	Majane et al., Peptides, 1990, 11, 969-972
	Allard et al., Brain Res., 1989, 500, 169-176
	Rothman, Synapse 1992, 12, 129-138
	Lake et al., Neurosci. Lett. 1991, 132, 29-32
	Payza, Peptides, 1987, 8, 1065-1074

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	

PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. T2315-907327US02	SERIAL NUMBER <u>10/801,695</u>
	APPLICANT	
	Laszlo Prokai	
	FILING DATE March 17, 2004	GROUP ART UNIT 1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Tan et al., Peptides 1999, 20, 1211-1217
	Gicquel et al., J. Med. Chem. 1994, 37, 3477-3481
	Weiner et al., Comput. Chem. 1986, 7, 230-252
	Stewart, J. Comput. Chem. 1989, 10, 209-220
	Houghten et al., J. Med. Chem. 1999, 42, 3743-3778
	Furka et al., J. Pept. Protein Res. 1991, 37, 487-493
	Lipinski et al., Adv. Drug. Deliv. Rev. 1997, 23, 3-25
	Ghose et al., J. Comput. Chem. 1988, 9, 80-90
	Pidgeon et al., J. Med. Chem. 1995, 38, 590-594
	Reichel et al., Pharm. Res. 1998, 15, 1270-1274
	Lingford et al., PubMed Abstract 12697627, also cited as Br. Med. Bull., 65,209-22(2003)
	Cador et al., PubMed 11958872, also cited as Neuroscience, 110/2,309-18(2002)
	Malin et al., PubMed Abstract 8804070, also cited as Peptides, 17/4,615-8(1996)
	Kelley et al., PubMed Abstract 12117573, also cited as Physiolo. Behav., 76/3,365-77(2002)
	Nystedt et al., PubMed 12354280, also cited as J. Neurochem., 82/6, 1330-42(2002)
	Tan et al., Peptides, 20, 1211-17 (1999)
	Prokai et al., Rapid Commun. Mass Spectrom. 2000, 14, 2414-2418
	Prokai et al., J. Med. Chem. 44, 1623-26 (2001), also cited at Chemical Abstract DN 135:163

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	